Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
Robert Z. Orlowski, MD, PhD / Nina Shah, MD - The Multiple Myeloma Workshop: Exploring the Convergence of Novel Therapeutic Platforms, Cell Therapy, and ASCT
Manage episode 286825986 series 9912
著作 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education の情報はPlayer FM及びコミュニティによって発見されました。著作権は出版社によって所持されます。そして、番組のオーディオは、その出版社のサーバから直接にストリーミングされます。Player FMで購読ボタンをタップし、更新できて、または他のポッドキャストアプリにフィードのURLを貼り付けます。
Go online to PeerView.com/ATX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new multiple myeloma (MM) CME program, two leading myeloma experts discuss key questions and controversies arising from the rapid validation of novel therapeutics for patients with MM who are autologous stem cell transplantation (ASCT) eligible. Although the use of ASCT remains a core therapeutic modality for MM, using ASCT in conjunction with innovative treatment options—including CAR-T cell therapy, proteasome inhibitors, immunomodulators, and antibodies such as, CD38 antibodies, BCMA-targeting antibody-drug conjugates, and bispecific antibodies—can substantially improve outcomes. These improvements have been observed across the continuum of care, from primary therapy to the management of relapsed/refractory disease (post-ASCT), as well as in the setting of minimal residual disease eradication. Hear our expert panel as they highlight these improvements and discuss the integration of approved and emerging novel therapies in MM. Upon completion of this activity, participants should be better able to: List current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in various multiple myeloma treatment settings, Describe efficacy and safety data surrounding novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new targeted agent classes in the management of ASCT-eligible patients with multiple myeloma, Develop regimens with novel components for ASCT-eligible patients with multiple myeloma, including as induction/consolidation or maintenance therapy, or in the setting of early relapse or refractory myeloma.